Skip to main
CCRN
CCRN logo

CCRN Stock Forecast & Price Target

CCRN Analyst Ratings

Based on 3 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Cross Country Healthcare has demonstrated a stabilization in gross margin at 20.0%, consistent with the previous quarter and exceeding expectations. The recent acquisition agreement with Aya Healthcare for $18.61 per share indicates a significant 67% premium over the stock's closing price prior to the announcement, reflecting strong investor confidence in the company's value. The adjusted timeline for the acquisition's completion to the second half of 2025 suggests a strategic approach to ensure a smooth transition, potentially benefiting stakeholders in the long term.

Bears say

Cross Country Healthcare's Q1/25 financial performance indicates significant challenges, with a 44% year-over-year decline in adjusted EBITDA to $8.6 million, despite exceeding expectations in a revenue shortfall context. The company's revenue also dropped 23% year-over-year to $293.4 million, falling short of both internal estimates and market consensus, largely reflecting ongoing softer demand conditions in the healthcare travel staffing sector. Furthermore, the downward revision of the 2025 revenue estimate to $1.166 billion, a reduction of 13.3% year-over-year from previous projections, underscores the ongoing adverse market dynamics affecting the company.

CCRN has been analyzed by 3 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cross Country Healthcare and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cross Country Healthcare (CCRN) Forecast

Analysts have given CCRN a Hold based on their latest research and market trends.

According to 3 analysts, CCRN has a Hold consensus rating as of Dec 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.91, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.91, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cross Country Healthcare (CCRN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.